228 related articles for article (PubMed ID: 18230832)
1. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
[TBL] [Abstract][Full Text] [Related]
2. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
3. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma].
Miyauchi A; Onishi T; Matsuzuka F; Hirai K; Kuma K; Takai S; Nakamoto K; Nakamura K; Nanjo S; Maeda M
Gan No Rinsho; 1986 Oct; 32(12):1519-24. PubMed ID: 3783976
[TBL] [Abstract][Full Text] [Related]
5.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
8. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
9. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
10. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
11. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
13. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
14. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
15. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
16. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG
Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446
[TBL] [Abstract][Full Text] [Related]
17. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
18. Correlation between calcitonin and carcinoembryonic antigen levels in medullary carcinoma of the thyroid.
Calmettes C; Moudktar MS; Milhaud G
Biomedicine; 1977 Mar; 27(2):52-4. PubMed ID: 861349
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
